Michelle Gee

6.3k citations

26 papers · 3.8k indexed · 2 hit papers · h-index 17

Impact in

Biological Psychiatry top 1%
- Tryptophan and brain disorders
Psychiatry and Mental health top 1%
- Dementia and Cognitive Impairment Research
- Epilepsy research and treatment

Papers in ⓘ

Biological Psychiatry 4
- Tryptophan and brain disorders 4
Research and Theory 1

Co-authors: Michael C. Irizarry (10 shared papers)Michio Kanekiyo (9 shared papers)Shobha Dhadda (8 shared papers)Christopher H. van Dyck (3 shared papers)Lynn D. Kramer (7 shared papers)Chad J. Swanson (3 shared papers)Sharon Cohen (1 shared paper)David Watson (1 shared paper)
Journals: Alzheimer s & Dementia (5 papers)Journal of Psychopharmacology (3 papers)SLAS DISCOVERY (2 papers)Alzheimer s Research & Therapy (2 papers)Neuroscience (2 papers)
Partner nations: United Kingdom United States Japan

In The Last Decade

Michelle Gee

24 papers receiving 3.7k citations

Hit Papers

align trajectories log scale

Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease 2024 · 61 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 Alzheimer s Research & Therapy
2022 New England Journal of Medicine

Peers

Countries citing papers authored by Michelle Gee

Since Specialization

Citations

This map shows the geographic impact of Michelle Gee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Gee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Gee more than expected).

Fields of papers citing papers by Michelle Gee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Gee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Gee. The network helps show where Michelle Gee may publish in the future.

Co-authors

The 25 scholars most cited alongside Michelle Gee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michelle Gee Line = papers co-authored together Michelle Gee links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Lecanemab in Early Alzheimer’s Disease New England Journal of Medicine ·Christopher H. van Dyck, Chad J. Swanson, Paul Aisen, Randall J. Bateman, Christopher Chen, Michelle Gee, Michio Kanekiyo, David Li, Larisa Reyderman, Sharon Cohen, Lutz Froelich, Sadao Katayama, Marwan Sabbagh, Bruno Vellas, David Watson, Shobha Dhadda, Michael C. Irizarry, Lynn D. Kramer, Takeshi Iwatsubo Hit paper breakdown →	2022	2741
2	A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial ofParoxetine in Children and Adolescents With Social Anxiety Disorder Archives of General Psychiatry ·Karen Dineen Wagner, R.M.F. Berard, Murray B. Stein, Erica Wetherhold, David Carpenter, Phillip Perera, Michelle Gee, Katherine Davy, Andrea Machin	2004	153
3	Perampanel, a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial‐onset seizures: Interim results from phase III, extension study 307 Epilepsia ·Gregory L. Krauss, Emilio Perucca, E. Ben‐Menachem, Patrick Kwan, Jerry J. Shih, David Squillacote, Haichen Yang, Michelle Gee, Jin Zhu, Antonio Laurenza	2012	94
4	Long‐term safety of perampanel and seizure outcomes in refractory partial‐onset seizures and secondarily generalized seizures: Results from phase III extension study 307 Epilepsia ·Gregory L. Krauss, Emilio Perucca, Elinor Ben‐Menachem, Patrick Kwan, Jerry J. Shih, Jean‐François Clément, Xuefeng Wang, Makarand Bagul, Michelle Gee, Jin Zhu, David Squillacote	2014	88
5	Activity-dependent slowing of conduction velocity provides a method for identifying different functional classes of c-fibre in the rat saphenous nerve Neuroscience ·Michelle Gee, Lynn Bry, B. Cotsell	1996	77
6	Enabling Lead Discovery for Histone Lysine Demethylases by High-Throughput RapidFire Mass Spectrometry SLAS DISCOVERY ·Sue Hutchinson, Melanie Leveridge, Michelle L. Heathcote, Peter Francis, Laura Williams, Michelle Gee, J. A. Muñoz, Bill Leavens, Anthony Shillings, Emma J. Jones, Paul Homes, Stuart M. Baddeley, Chun‐wa Chung, Angela Bridges, Argyrides Argyrou	2011	72
7	Effects of peer-mentoring on stress and anxiety levels of undergraduate nursing students: An integrative review Journal of Professional Nursing ·Melissa Kachaturoff, Meriam Caboral‐Stevens, Michelle Gee, Virginia M. Lan	2019	71
8	Perampanel Study 207: long-term open-label evaluation in patients with epilepsy Acta Neurologica Scandinavica ·Ivan Rektor, Gregory L. Krauss, Michal Bar, Victor Biton, J. A. Klapper, Nerija Vaičienė-Magistris, Robert Kuba, David Squillacote, Michelle Gee, Dinesh Kumar	2012	66
9	Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease Alzheimer s Research & Therapy ·Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven M. Hersch, André Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk D. Purcell, Shobha Dhadda, Michael C. Irizarry, Lynn D. Kramer Hit paper breakdown →	2024	61
10	Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease The Journal of Prevention of Alzheimer s Disease ·Sarah Cohen, Christopher H. van Dyck, Michelle Gee, T. Doherty, Michio Kanekiyo, Shobha Dhadda, David K.B. Li, Steven M. Hersch, Michael C. Irizarry, L. D. Kramer	2023	50
11	Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder American Journal of Obstetrics and Gynecology ·Meir Steiner, Angelica Lindén Hirschberg, Richard Bergeron, Fiona Holland, Michelle Gee, Elisabeth Van Erp	2005	50
12	Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR Journal of Psychopharmacology ·K. Hewett, Michelle Gee, Alok Krishen, Hans-Peter Wunderlich, Alfred Le Clus, G. Evoniuk, Jack G. Modell	2009	49
13	Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR Journal of Psychopharmacology ·K. Hewett, W. Chrzanowski, Mark F. Schmitz, A Savela, Vihra Milanova, Michelle Gee, Alok Krishen, Lily Millen, MO Leary, Jack G. Modell	2008	47
14	The Relationship between Cutaneous C Fibre Type and Antidromic Vasodilatation in the Rabbit and the Rat The Journal of Physiology ·Michelle Gee, Lynn Bry, B. Cotsell	1997	41
15	Lead Discovery for Human Kynurenine 3-Monooxygenase by High-Throughput RapidFire Mass Spectrometry SLAS DISCOVERY ·Denise M. Lowe, Michelle Gee, Carl Haslam, Bill Leavens, Erica Christodoulou, Paul Hissey, Philip Hardwicke, Argyrides Argyrou, Scott P. Webster, Damian J. Mole, Kris Wilson, Margaret Binnie, Beverley A. Yard, Tony W. Dean, John Liddle, Iain Uings, Jonathan P. Hutchinson	2013	31
16	Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach Journal of Psychopharmacology ·Amir Inamdar, Emilio Merlo‐Pich, Michelle Gee, Clare Makumi, Prafull Mistry, Jon Robertson, Erik Steinberg, Stefano Zamuner, Susan M. Learned, Robert Alexander, Emiliangelo Ratti	2014	20
17	The relationship between axonal spike shape and functional modality in cutaneous C-fibres in the pig and rat Neuroscience ·Michelle Gee, Lynn Bry, Sarah Basile, Fr.-K. Pierau, B. Cotsell	1999	20
18	Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects—a MissionAD tau sub-study Alzheimer s Research & Therapy ·Santiago Bullich, André Mueller, Susan De Santi, Norman Koglin, Stephen Krause, June Kaplow, Michio Kanekiyo, Núria Roé-Vellvé, Audrey Perrotin, Aleksandar Jovalekic, David Scott, Michelle Gee, Andrew Stephens, Michael C. Irizarry	2022	16
19	Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease Annals of Neurology ·Joshua D. Grill, Charlene Flournoy, Shobha Dhadda, Karin Ernström, Reisa A. Sperling, Doris P. Molina‐Henry, Kate Tranotti, Russell Harris, Michio Kanekiyo, Michelle Gee, Michael C. Irizarry, Lynn D. Kramer, Paul Aisen, Rema Raman	2023	16
20	P.2.c.006 Efficacy and safety of bupropion extended release in elderly patients with major depressive disorder European Neuropsychopharmacology ·W. Chrzanowski, Roxanne Rousseau, K. Hewett, Michelle Gee, Donna S. Wightman, Nathalie Richard, Jack G. Modell, Elizabeth P. Goodale	2006	4

About Michelle Gee

Michelle Gee is a scholar working on Biological Psychiatry, Research and Theory, Psychiatry and Mental health, Physiology and Pharmacology, having authored 26 papers that have together received 3.8k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (7 papers), Dementia and Cognitive Impairment Research (6 papers), Tryptophan and brain disorders (4 papers), Pharmacological Effects and Toxicity Studies (3 papers), Electroconvulsive Therapy Studies (3 papers), Epilepsy research and treatment (3 papers), Pain Mechanisms and Treatments (3 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). The work is most often cited by research in Biological Psychiatry (268 citations), Psychiatry and Mental health (1.3k citations), Physiology (1.7k citations), Neurology (504 citations) and Pharmacology (554 citations). Michelle Gee has collaborated with scholars based in United Kingdom, United States and Japan. Frequent co-authors include Michael C. Irizarry, Michio Kanekiyo, Shobha Dhadda, Christopher H. van Dyck, Lynn D. Kramer, Chad J. Swanson, Sharon Cohen, David Watson, Paul Aisen and Bruno Vellas. Their work appears in journals such as Alzheimer s & Dementia, Journal of Psychopharmacology, SLAS DISCOVERY, Alzheimer s Research & Therapy and Neuroscience.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact